Novel Self-Amplifying RNA Lipid Nanoparticle Vaccines

The increase of the SARS-CoV-2 into a global pandemic within a few months of onset motivates developing a rapidly scalable vaccine.

In an article published in nature communication this year, the Department of Infectious Diseases, Imperial College London group (Paul F. McKay et al.), demonstrates vaccine formulation using a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nanoparticle (LNP).

self-amplifying RNA Lipid Nanoparticle Vaccines

In a set of experiments, they observed the too high generation of dose-dependent SARS-CoV-2 antibodies titers in mice samples, as well as substantial neutralization of both a wild-type virus and pseudo-virus.

With several types of characterizations, they showed that the neutralization is comparative to the number of IgG’s and of greater magnitude than recovered COVID-19 patients.

On the other hand, the saRNA-LNP immunizations stimulated a Th1 biased reaction in mice samples, and as a result, there were no antibody-dependent enhancement (ADE) observed.

Lastly, the team followed high cellular responses, as characterized by IFN-γ production, upon re-stimulation with SARS-CoV-2 peptides. The paper’s data and this impressive work give an insight into the vaccine development and validation of immunogenicity to enable rapid translation of vaccine research to the clinic.

T&T Scientific in the Fight Against COVID-19: Contract Research, Development, and Manufacturing Organization Support (CRO,CDMO) for Lipid Nanoparticles (LNP) Therapeutics and Vaccines.
Our team at T&T Scientific is dedicated to helping researchers and scientists around the world with development and GMP manufacturing of lipid nanoparticle (LNP) vaccines and therapeutics to help in the battle against Coronavirus.


  1. McKay, P.F., Hu, K., Blakney, A.K., Samnuan, K., Brown, J.C., Penn, R., Zhou, J., Bouton, C.R., Rogers, P., Polar, K. and Lin, P.J., 2020. self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nature communications, 11(1), pp.1-7.

Leave a comment

Please note, comments must be approved before they are published